Search Result

Pathways Recommended:	PI3K/Akt/mTOR

Results for "

AKT Kinase Inhibitor (Standard)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (10) AMPK (2) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (11) Aurora Kinase (2) Autophagy (6) Bcl-2 Family (2) Bcr-Abl (1) c-Kit (1) c-Met/HGFR (2) Caspase (3) CDK (2) Cholinesterase (ChE) (1) EGFR (3) ERK (1) FLT3 (1) HBV (1) IGF-1R (1) Influenza Virus (1) JNK (3) mTOR (1) Myosin (1) NF-κB (3) NO Synthase (1) NOD-like Receptor (NLR) (1) p38 MAPK (1) Parasite (1) PARP (2) Phosphodiesterase (PDE) (1) PI3K (3) PKA (1) PKC (3) Reactive Oxygen Species (ROS) (1) Reference Standards (19) ROS Kinase (1) Src (1) STAT (2) TRP Channel (1) VEGFR (1) Wnt (1)
By Research Areas:	Cancer (19) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (5) Metabolic Disease (3) Neurological Disease (3)

By Targets:

Akt (10)

AMPK (2)

Anaplastic lymphoma kinase (ALK) (1)

Apoptosis (11)

Aurora Kinase (2)

Autophagy (6)

Bcl-2 Family (2)

Bcr-Abl (1)

c-Kit (1)

c-Met/HGFR (2)

Caspase (3)

CDK (2)

Cholinesterase (ChE) (1)

EGFR (3)

ERK (1)

FLT3 (1)

HBV (1)

IGF-1R (1)

Influenza Virus (1)

JNK (3)

mTOR (1)

Myosin (1)

NF-κB (3)

NO Synthase (1)

NOD-like Receptor (NLR) (1)

p38 MAPK (1)

Parasite (1)

PARP (2)

Phosphodiesterase (PDE) (1)

PI3K (3)

PKA (1)

PKC (3)

Reactive Oxygen Species (ROS) (1)

Reference Standards (19)

ROS Kinase (1)

Src (1)

STAT (2)

TRP Channel (1)

VEGFR (1)

Wnt (1)

By Research Areas:

Cancer (19)

Cardiovascular Disease (1)

Infection (2)

Inflammation/Immunology (5)

Metabolic Disease (3)

Neurological Disease (3)

Inhibitors & Agonists

Natural
Products

Targets Recommended: Akt

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15431R

Capivasertib (Standard) AZD5363 (Standard)	Akt Autophagy Reference Standards	Cancer
Capivasertib (Standard) is the analytical standard of Capivasertib. This product is intended for research and analytical applications. Capivasertib (AZD5363) is an orally active and potent pan-AKT kinase inhibitor with IC50 of 3, 7 and 7 nM for Akt1,Akt2 and Akt3, respectively.

HY-13072R

Cenisertib (Standard) AS-703569 (Standard); R-763 (Standard)	Aurora Kinase Bcr-Abl Akt STAT FLT3 Reference Standards	Cancer
Cenisertib (Standard) is the analytical standard of Cenisertib. This product is intended for research and analytical applications. Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .

HY-N2081R

Skimmianine (Standard)	Reference Standards Cholinesterase (ChE) PI3K Akt NF-κB	Neurological Disease Inflammation/Immunology Cancer
Skimmianine (Standard) is the analytical standard of Skimmianine. This product is intended for research and analytical applications. Skimmianine is an orally active furoquiniline alkaloid present mainly in the Rutaceae family. Skimmianine has analgesic, antispastic, sedative, and anti-inflammatory properties. Skimmianine inhibits acetylcholinesterase (AChE) (IC₅₀ = 8.6 μg/mL). Skimmianine exhibits cytotoxicity against a variety of cancer cell lines and genotoxicity. Skimmianine has antioxidant and anti-inflammatory effects on ischemia-reperfusion (IR) injury. Skimmianine exerts anti-inflammatory effects through activation of the phosphatidylinositol-3-kinase (PI3K)-protein kinase B (AKT) pathway. Skimmianine is neuroprotective by targeting the NF-κB activation pathway to prevent neuroinflammation. Skimmianine inhibits the release of histamine, intracellular Ca ²⁺ signaling and protein kinase C signaling .

HY-16558R

Butein (Standard) 2’,3,4,4’-tetrahydroxy Chalcone (Standard)	Reference Standards EGFR Autophagy Apoptosis Phosphodiesterase (PDE)	Cancer
Butein (Standard) is the analytical standard of Butein. This product is intended for research and analytical applications. Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).

HY-10230R

Midostaurin (Standard) PKC412 (Standard); CGP 41251 (Standard)	Reference Standards PKC VEGFR c-Kit NO Synthase Apoptosis	Cancer
Midostaurin (Standard) is the analytical standard of Midostaurin. This product is intended for research and analytical applications. Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, *Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ* and VEGFR1/2 with IC₅₀s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .

HY-13404R

Capmatinib (Standard) INC280 (Standard); INCB28060 (Standard)	Reference Standards c-Met/HGFR Apoptosis	Cancer
Capmatinib (Standard) is the analytical standard of Capmatinib. This product is intended for research and analytical applications. Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC₅₀=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-N0281R

Daphnetin (Standard) 7,8-Dihydroxycoumarin (Standard)	Reference Standards EGFR PKA PKC Autophagy Apoptosis AMPK Akt mTOR Reactive Oxygen Species (ROS) Caspase Bcl-2 Family PARP Parasite	Inflammation/Immunology Cancer
Daphnetin (Standard) is the analytical standard of Daphnetin. This product is intended for research and analytical applications. Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative can be found in plants of the Genus Daphne, is a potent, oral active protein kinase inhibitor, with IC₅₀s of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively. Daphnetin triggers ROS-induced cell apoptosis and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway. Daphnetin has anti-inflammation activitity and inhibits TNF-α, IL-1 , ROS, and MDA production. Daphnetin has schizontocidal activity against malaria parasites. Daphnetin can be used for rheumatoid arthritis , cancer and anti-malarian research .

HY-10249AR

AKT Kinase Inhibitor (Standard)	Reference Standards Akt	Cancer
AKT Kinase Inhibitor (Standard) is the analytical standard of AKT Kinase Inhibitor (HY-10249A). This product is intended for research and analytical applications. AKT Kinase Inhibitor is an Akt kinase inhibitor with anti-tumor activity .

HY-10249DR

AKT Kinase Inhibitor hydrochloride (Standard)	Reference Standards Akt	Cancer
AKT Kinase Inhibitor hydrochloride (Standard) is the analytical standard of AKT Kinase Inhibitor hydrochloride (HY-10249D). This product is intended for research and analytical applications. AKT Kinase Inhibitor hydrochloride is an Akt kinase inhibitor with anti-tumor activity . AKT Kinase Inhibitor hydrochloride is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10971R

Alisertib (Standard) MLN 8237 (Standard)	Aurora Kinase Autophagy Apoptosis Reference Standards	Cancer
Alisertib (Standard) is the analytical standard of Alisertib. This product is intended for research and analytical applications. Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .

HY-13326R

ASP3026 (Standard)	Anaplastic lymphoma kinase (ALK) Apoptosis ROS Kinase Caspase PARP IGF-1R STAT Akt JNK	Cancer
ASP3026 (Standard) is the analytical standard of ASP3026. This product is intended for research and analytical applications. ASP3026 is a selective and orally active inhibitor of anaplastic lymphoma kinase (ALK). ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC50 value of 3.5 nM. ASP3026 can inhibit the phosphorylation of IGF-1R, STAT3, AKT and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. ASP3026 can be used in anti-tumor research .

HY-116035R

Nimbolide (Standard)	Wnt NF-κB CDK Apoptosis Reference Standards	Cancer
Nimbolide (Standard) is the analytical standard of Nimbolide. This product is intended for research and analytical applications. Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and CDK4/CDK6 kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-13404CR

Capmatinib dihydrochloride hydrate (Standard) INC280 dihydrochloride hydrate (Standard); INCB-28060 dihydrochloride hydrate (Standard)	c-Met/HGFR Apoptosis Reference Standards	Cancer
Capmatinib (dihydrochloride hydrate) (Standard) is the analytical standard of Capmatinib (dihydrochloride hydrate). This product is intended for research and analytical applications. Capmatinib (INC280; INCB28060) dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-N0031R

Plantamajoside (Standard)	Reference Standards NF-κB PI3K Apoptosis Autophagy p38 MAPK Src	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Plantamajoside (Standard) is the analytical standard of Plantamajoside. This product is intended for use in research and analytical applications. Plantamajoside is an orally active phenylpropanoid glycoside. Plantamajoside can be isolated from Plantago asiatica L.(Plantaginaceae). Plantamajoside inactivates NF-κB, *PI3K/akt, induces Apoptosis, and improves Autophagy. Plantamajoside regulates MAPK, integrin-linked kinase/c-Src. Plantamajoside inhibits* multiple cancers, improves lung and kidney damage. Plantamajoside has neuroprotective and anti-inflammatory effects .

HY-N0699R

Daphnoretin (Standard) Dephnoretin (Standard); Thymelol (Standard)	Reference Standards PKC NOD-like Receptor (NLR) Apoptosis HBV Caspase Akt JNK PI3K CDK Influenza Virus Bcl-2 Family	Infection Inflammation/Immunology Cancer
Daphnoretin (Dephnoretin; Thymelol) (Standard) is the analytical standard of Daphnoretin (HY-N0699). This product is used for research and analytical applications. Daphnoretin is a protein kinase C (PKC) activator that can inhibit the expression of hepatitis B virus (HBV) surface antigen (HBsAg) and has antiviral activity. Daphnoretin exerts its anti-tumor effect by inhibiting the activation of the *PI3K/AKT* signaling pathway, triggering the mitochondrial apoptosis pathway. Daphnoretin alleviates chondrocyte apoptosis and inflammatory responses by inhibiting endoplasmic reticulum stress and the activation of the NLRP3 inflammasome. Daphnoretin can regulate the differentiation and maturation of dendritic cells, by down-regulating the phosphorylation level of JNK, inhibiting its immune stimulating function, thereby playing a protective role in skin transplant rejection reactions.

HY-10249R

GSK-690693 (Standard)	Reference Standards Akt AMPK Autophagy	Cancer
GSK-690693 (Standard) is the analytical standard of GSK-690693 (HY-10249). This product is intended for research and analytical applications. GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC₅₀s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation .

HY-100932R

ML-9 (Standard)	Myosin Reference Standards	Cancer
ML-9 (Standard) is the analytical standard of ML-9 (HY-100932). This product is intended for research and analytical applications. ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity . ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively . ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation .

HY-107597R

Halicin (Standard) SU3327 (Standard)	Reference Standards JNK	Metabolic Disease Inflammation/Immunology
Halicin (Standard) is the analytical standard of Halicin (HY-107597). This product is intended for research and analytical applications. Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC₅₀ of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC₅₀ of 239 nM. Halicin shows less active against p38α and Akt K_inase .

HY-109061R

Lazertinib (Standard) YH25448 (Standard); GNS-1480 (Standard)	Apoptosis Akt TRP Channel EGFR ERK Reference Standards	Infection Neurological Disease Metabolic Disease Cancer
Lazertinib (Standard) is the analytical standard of Lazertinib (HY-109061). This product is intended for research and analytical applications. Lazertinib (YH25448) is a potent, selective, CNS-penetrant, orally available and irreversible EGFR tyrosine K_inase inhibitor, exhibiting high selectivity for activating (EGFRm) and T790M resistance mutations. Lazertinib inhibits phosphorylation of EGFR, AKT and ERK, leading to apoptosis and suppression of tumor growth in mouse H1975-luc brain metastasis xenograft models. Lazertinib can be used in the study of non-small cell lung cancer .

HY-109061BR

Lazertinib mesylate (Standard) YH25448 mesylate (Standard); GNS-1480 mesylate (Standard)	Reference Standards	Cancer
Lazertinib mesylate (Standard) is the analytical standard of Lazertinib (mesylate) (HY-109061B). This product is intended for research and analytical applications. Lazertinib (YH25448) mesylate is a potent, selective, CNS-penetrant, orally available and irreversible EGFR tyrosine K_inase inhibitor, exhibiting high selectivity for activating (EGFRm) and T790M resistance mutations. Lazertinib mesylate inhibits phosphorylation of EGFR, AKT and ERK, leading to apoptosis and suppression of tumor growth in mouse H1975-luc brain metastasis xenograft models. Lazertinib mesylate can be used in the study of non-small cell lung cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure